BioNTech to highlight clinical results from CAR T program
By The Science Advisory Board staff writersNovember 1, 2021
BNT211 is an autologous CAR T-cell therapy that targets oncofetal antigen claudin 6 (CLDN6), according to the company. BNT211 is currently in trials for assessment as a monotherapy, as well as in combination with a CLDN6 mRNA-based vaccine (CARVac), for the treatment of relapsed or refractory advanced solid tumors, BioNTech said.